Novo Nordisk A/S (NYSE:NVO) Shares Gap Down - Should You Sell?

Novo Nordisk A/S (NYSE:NVO - Get Free Report) shares gapped down prior to trading on Friday . The stock had previously closed at $66.15, but opened at $64.40. Novo Nordisk A/S shares last traded at $64.10, with a volume of 6,047,157 shares trading hands.

Analyst Upgrades and Downgrades

A number of research firms have commented on NVO. StockNews.com raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. BNP Paribas assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating for the company. Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Finally, BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $135.00.

Novo Nordisk A/S Trading Down 2.8%

The firm has a market cap of $288.42 billion, a price-to-earnings ratio of 19.57, a PEG ratio of 0.90 and a beta of 0.65. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The business has a fifty day moving average of $67.59 and a two-hundred day moving average of $84.91.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. The business had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of hedge funds have recently bought and sold shares of the company. Center for Financial Planning Inc. lifted its holdings in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after acquiring an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL lifted its holdings in Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after acquiring an additional 300 shares during the last quarter. Park Square Financial Group LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Transce3nd LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $33,000. Finally, North Capital Inc. bought a new stake in shares of Novo Nordisk A/S during the first quarter valued at approximately $27,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.